Triglycerides: Emerging Targets in Diabetes Care? Review of Moderate Hypertriglyceridemia in Diabetes
Purpose of Review
Moderate hypertriglyceridemia is exceedingly common in diabetes, and there is growing evidence that it contributes to residual cardiovascular risk in statin-optimized patients. Major fibrate trials yielded inconclusive results regarding the cardiovascular benefit of lowering triglycerides, although there was a signal for improvement among patients with high triglycerides and low high-density lipoprotein (HDL)—the “diabetic dyslipidemia” phenotype. Until recently, no trials have examined a priori the impact of triglyceride lowering in patients with diabetic dyslipidemia, who are likely among the highest cardiovascular-risk patients.
In the recent REDUCE IT trial, omega-3 fatty acid icosapent ethyl demonstrated efficacy in lowering cardiovascular events in patients with high triglycerides, low HDL, and statin-optimized low-density lipoprotein (LDL). The ongoing PROMINENT trial is examining the impact of pemafibrate in a similar patient population.
Emerging evidence suggests that lowering triglycerides may reduce residual cardiovascular risk, especially in high-risk patients with diabetic dyslipidemia.
KeywordsHypertriglyceridemia Type 2 diabetes Diabetic dyslipidemia Medications
MJC is supported by a Career Development Award from VHA Health Services Research & Development (CDA 13-261) and acknowledges support from the Center of Innovation to Accelerate Discovery and Practice Transformation (CIN 13-410). Additionally, research reported in this publication was supported by the National Institutes of Health under Award No. T32DK007012 (ASA).
Compliance with Ethical Standards
Conflict of Interest
John R. Guyton has received research support from Sanofi, Regeneron Pharmaceuticals, and Amarin Pharmaceuticals.
Anastasia-Stefania Alexopoulos, Ali Qamar, Kathryn Hutchins, Matthew J. Crowley, Bryan C. Batch, and John R. Guyton declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Centers for Disease Control and Prevention. National diabetes fact sheet. Available at: https://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf 2011 [Accessed 12/10/2019].
- 2.•• Nichols GA, Philip S, Reynolds K, Granowitz CB, Fazio S. Increased cardiovascular risk in hypertriglyceridemic patients with statin-controlled LDL cholesterol. J Clin Endocrinol Metab. 2018;103(8):3019–27 A longitudinal cohort study demonstrating higher cardiovascular risk in statin-controlled patients with moderate triglyceride elevations. PubMedGoogle Scholar
- 5.Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317(20):1237–45.Google Scholar
- 6.Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849–61.Google Scholar
- 8.Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs high-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341(6):410–8.Google Scholar
- 9.Scott R, O'Brien R, Fulcher G, Pardy C, D'Emden M, Tse D, et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care. 2009;32(3):493–8.PubMedPubMedCentralGoogle Scholar
- 10.Bezafibrate Infarction Prevention Study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation. 2000;102(1):21–7.Google Scholar
- 12.Toth PP, Granowitz C, Hull M, Liassou D, Anderson A, Philip S. High triglycerides are associated with increased cardiovascular events, medical costs, and resource use: a real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk. J Am Heart Assoc. 2018;7(15):e008740.PubMedPubMedCentralGoogle Scholar
- 18.Myocardial Infarction G, Investigators CAEC, Stitziel NO, Stirrups KE, Masca NG, Erdmann J, et al. Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease. N Engl J Med. 2016;374(12):1134–44.Google Scholar
- 19.Tg, Hdl Working Group of the Exome Sequencing Project NHL, Blood I, Crosby J, Peloso GM, Auer PL, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371(1):22–31.Google Scholar
- 22.Varbo A, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation. 2013;128(12):1298–309.PubMedGoogle Scholar
- 26.• Rosenblit PD. Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile? Cardiovasc Diabetol. 2016;15:95 A focused review on the impact of antihyperglycemic medications on lipid profiles, including newer agents such as GLP-1 receptor agonists and SGLT2 inhibitors. PubMedPubMedCentralGoogle Scholar
- 35.•• Hjerpsted JB, Flint A, Brooks A, Axelsen MB, Kvist T, Blundell J. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obes Metab. 2018;20(3):610–9 A randomized controlled trial demonstrating reduction in both fasting and postprandial triglycerides in patients taking GLP-1 receptor agonist semaglutide versus placebo. PubMedGoogle Scholar
- 38.• d'Emden M, Amerena J, Deed G, Pollock C, Cooper ME. SGLT2 inhibitors with cardiovascular benefits: transforming clinical care in Type 2 diabetes mellitus. Diabetes Res Clin Pract. 2018;136:23–31 A comprehensive review of SGLT2 inhibitors and their performance in cardiovascular outcomes trials. PubMedGoogle Scholar
- 39.• Hayashi T, Fukui T, Nakanishi N, Yamamoto S, Tomoyasu M, Osamura A, et al. Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. Cardiovasc Diabetol. 2017;16(1):8 A study demonstrating that while SGLT2 inhibitor dapagliflozin may raise LDL-C, it suppresses small dense, atherogenic LDL. PubMedPubMedCentralGoogle Scholar
- 41.• Williams L, Rhodes KS, Karmally W, Welstead LA, Alexander L, Sutton L, et al. Familial chylomicronemia syndrome: bringing to life dietary recommendations throughout the life span. J Clin Lipidol. 2018;12(4):908–19 While this paper is geared towards patients with LPL deficiency, it provides a good overview of dietary approaches to lowering triglycerides. PubMedGoogle Scholar
- 48.•• Araki E, Yamashita S, Arai H, Yokote K, Satoh J, Inoguchi T, et al. Effects of pemafibrate, a novel selective PPAR alpha modulator, on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2018;41(3):538–46 An important phase III trial of pemafibrate in patients with T2DM and hypertriglyceridemia which demonstrated good efficacy of this new fibrate in lowering triglycerides. PubMedGoogle Scholar
- 49.•• Arai H, Yamashita S, Yokote K, Araki E, Suganami H, Ishibashi S, et al. Efficacy and safety of pemafibrate versus fenofibrate in patients with high triglyceride and low HDL cholesterol levels: a multicenter, placebo-controlled, double-blind, randomized trial. J Atheroscler Thromb. 2018;25(6):521–38 An important phase III trial of pemafibrate, examining the effiacy and safety of this new agent in patients with the atherogenic dyslipidemia; alongside ref 47, this trial has set the stage for the ongoing PROMINENT study.PubMedPubMedCentralGoogle Scholar
- 50.Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet. 2009;374(9684):126–35.PubMedGoogle Scholar
- 55.Durrington PN, Bhatnagar D, Mackness MI, Morgan J, Julier K, Khan MA, et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart. 2001;85(5):544–8.PubMedPubMedCentralGoogle Scholar
- 57.Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol. 2011;108(5):682–90.PubMedGoogle Scholar
- 58.AstraZeneca Pharmaceuticals. Epanova prescribing information. 2014.Google Scholar
- 59.GlaxoSmithKline. Lovaza prescribing information. 2015.Google Scholar
- 60.Amarin Corporation. Vascepa prescibing information. 2017.Google Scholar
- 64.Investigators OT, Bosch J, Gerstein HC, Dagenais GR, Diaz R, Dyal L, et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367(4):309–18.Google Scholar
- 65.Risk and Prevention Study Collaborative Group, Roncaglioni MC, Tombesi M, Avanzini F, Barlera S, et al. n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med. 2013;368(19):1800–8.Google Scholar
- 66.Manson JE, Cook NR, Christen W, Bassuk SS, Mora S, Gibson H, et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med. 2019;381(1):23–32.Google Scholar
- 67.Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369(9567):1090–8.Google Scholar
- 68.•• Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2018;380:11–22 A recent and impactful study which showed cardiovascular benefit with icosapent ethyl in a high-risk population with moderate hypertriglyceridemia and at-goal LDL levels. PubMedGoogle Scholar
- 70.• Fraser DA, Wang, X, Alonso, C, Lek, S, Skjaeret, T, Schuppan, D. Icosabutate, a novel structurally engineered fatty-acid, exhibits potent anti-inflammatory and anti-fibrotic effects in a dietary mouse model resembling progressive human NASH. [Poster]. In press 2018. Preliminary evidence demonstrating that icosabutate may have anti-fibrotic properties. Google Scholar
- 71.• Fraser DA, Thorbek DD, Allen B, Thrane SW, Skjaeret T, Friedman SL, Feigh, M. A liver-targeted structurally engineered fatty acid, icosabutate, potently reduces hepatic pro-fibrotic gene expression and improves glycemic control in an obese diet-induced mouse model of NASH. [Poster]. In press 2018. Preliminary evidence demonstrating that icosabutate may improve glycemic control as well as reduce pro-fibrotic gene expression. Google Scholar
- 76.Group HTC, Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203–12.Google Scholar
- 77.Grundy SM, Vega GL, McGovern ME, Tulloch BR, Kendall DM, Fitz-Patrick D, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med. 2002;162(14):1568–76.PubMedGoogle Scholar
- 78.Elam MB, Hunninghake DB, Davis KB, Garg R, Johnson C, Egan D, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial Arterial Disease Multiple Intervention Trial. JAMA. 2000;284(10):1263–70.PubMedGoogle Scholar
- 81.Investigators A-H, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255–67.Google Scholar
- 83.• Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23(Suppl 2):1–87 Updated AACE guidelines on the management of dyslipidemia. PubMedGoogle Scholar
- 85.• Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the Management of Blood Cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol. 2018. Updated cardiology guidelines on the management of dyslipidemia. Google Scholar
- 86.National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–421.Google Scholar
- 88.Ooi EM, Barrett PH, Chan DC, Watts GF. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin Sci (Lond). 2008;114(10):611–24.Google Scholar
- 89.• Digenio A, Dunbar RL, Alexander VJ, Hompesch M, Morrow L, Lee RG, et al. Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes. Diabetes Care. 2016;39(8):1408–15 A phase II trial in patients with diabetes and hypertriglyceridemia which showed improvements in dyslipidemia and insulin sensitivity with the use of apoCIII inhibitor volanesorsen. PubMedGoogle Scholar
- 90.• Gaudet D, Alexander V, Arca M, Jones A, Stroes E, Bergeron J, et al. The APPROACH study: a randomized, double-blind, placebo-controlled, phase 3 study of volanesorsen administered subcutaneously to patients with familial chylomicronemia syndrome (FCS). Atherosclerosis. 2017;283:e10 Abstracts. Early evidence revealing safety concerns with the use of volanesorsen. Google Scholar
- 91.• Dewey FE, Gusarova V, Dunbar RL, O'Dushlaine C, Schurmann C, Gottesman O, et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N Engl J Med. 2017;377(3):211–21 An important phase I study highlighting the triglyceride-lowering potential of evinacumab (mAb to ANGPTL3), and its potential to decrease atherosclerosis in mice. PubMedPubMedCentralGoogle Scholar
- 92.• Graham MJ, Lee RG, Brandt TA, Tai LJ, Fu W, Peralta R, et al. Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides. N Engl J Med. 2017;377(3):222–32 A phase I study which demonstrated that targeting ANGPTL3 using mRNA leads to a reduction in both triglycerides, and LDL-C. PubMedGoogle Scholar